Cointime

Artielle ImmunoTherapeutics

company

About

Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.

  • 1 - 10

Highlights

Total Funding Amount
$11M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$11M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2004
Number Of Employee
1 - 10
Operating Status
Active

Artielle ImmunoTherapeutics, Inc., a biopharmaceutical company, develops recombinant T-cell receptor ligands (RTLs) to treat T-cell mediated inflammatory diseases. It develops RTL1000, a compound for the treatment of multiple sclerosis. The company focuses on the development of therapeutics for the treatment of autoimmune diseases that include multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, optic neuritis, and other diseases. Artielle ImmunoTherapeutics, Inc. was founded in 2004 and is based in Tigard, Oregon.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$11M
Artielle ImmunoTherapeutics has raised a total of $11M in funding over 2 rounds. Their latest funding was raised on Jun 23, 2004 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 23, 2004 Series A $11M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Artielle ImmunoTherapeutics is funded by 2 investors. Northwest Technology Ventures and Tenex Greenhouse Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Northwest Technology Ventures — Series A
Tenex Greenhouse Ventures — Series A
Cointime
Содержание
компания